Advances in the management of inflammatory bowel disease

Our understanding of inflammatory bowel diseases (IBD) is constantly evolving, and many new treatment options have emerged recently. This review critically examines the evidence for these new developments and aims to provide an overview for medical professionals involved in the care of patients with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal medicine journal 2010-04, Vol.40 (4), p.258-264
Hauptverfasser:	Grimpen, F., Pavli, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Biological Products - pharmacokinetics Biological Products - therapeutic use Crohn's disease Disease Management Gastrointestinal Agents - pharmacokinetics Gastrointestinal Agents - therapeutic use Humans IBD Immunosuppressive Agents - pharmacokinetics Immunosuppressive Agents - therapeutic use Inflammatory Bowel Diseases - diagnosis Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - immunology review management ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Our understanding of inflammatory bowel diseases (IBD) is constantly evolving, and many new treatment options have emerged recently. This review critically examines the evidence for these new developments and aims to provide an overview for medical professionals involved in the care of patients with IBD. Proposed changes in the use of aminosalicylates, immunosuppressants and biological agents are described, and the evidence for several promising novel agents is reviewed.
ISSN:	1444-0903 1445-5994
DOI:	10.1111/j.1445-5994.2010.02163.x